 | Jeffrey S GinsbergDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada | Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada | ... |
KOL Resume for Jeffrey S Ginsberg (disease, venous, venous embolism thrombosis, embolism, thrombosis)
| Year | |
|---|---|
| 2022 | Department of Medicine, McMaster University, Hamilton, Ontario, Canada |
| 2021 | Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada |
| 2020 | Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada |
| 2019 | Department of Medicine, McMaster University, Hamilton, ON, Canada |
| 2018 | Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada. |
| 2017 | Department of Medicine, McMaster University, Hamilton, Canada |
| 2016 | McMaster Univ. Medical Ctr., Hamilton, Canada |
| 2015 | Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada |
| 2014 | McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada |
| 2013 | McMaster University, Hamilton Health Sciences, Hamilton, Canada |
| 2012 | Department of Medicine, McMaster University Medical Center, Hamilton, Canada |
| 2010 | Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada (J.G.). |
| 2009 | McMaster University and the Henderson Research Centre, Hamilton, ON, Canada |
| 2008 | Department of Medicine, McMaster University Medical Center, Hamilton, ON |
| 2007 | From Women's College Hospital, Toronto, Ontario, Canada; North Shore Hospital, Takapuna, New Zealand; McMaster University, Hamilton, Ontario, Canada; and the University of Ottawa, Ottawa, Ontario, Canada. Medicine, McMaster University, Hamilton, ON, Canada McMaster University Medical Center |
| 2006 | From McMaster University and the Henderson Research Centre, Hamilton, Ontario, Canada; University of Ottawa, Ottawa, Ontario, Canada; Dalhousie University, Halifax, Nova Scotia, Canada; and University of Western Ontario, London, Ontario, Canada. Henderson Research Center, McMaster University, Hamilton, ON, Canada |
| 2005 | Departments of Medicine, Clinical Epidemiology and Biostatistics Jeffrey S Ginsberg, MD, Professor, Department of Medicine, McMaster University |
| 2004 | From McMaster University, Hamilton, Ontario L8N 3Z5, Canada. Henderson Research Center, Hamilton, Ontario |
| 2003 | From the Population Health Research Institute (S.S.A., S.Y., J.P.) and Henderson Research Centre (J.S.G., J.H.), McMaster University, Hamilton, Canada, and the Divisions of Cardiology and Thrombosis, Department of Medicine (S.S.A., S.Y., J.P., J.S.G., J.H.), McMaster University, Hamilton, Canada. Henderson Research Centre, Hamilton, Ont. (C.K., J.S.G., J.A.J., B.M., J.I.W., M.G.) Hamilton Health Sciences, Hamilton, ON, Canada McMaster University, USA |
| 2002 | From University of Rochester School of Medicine and Dentistry, Rochester, New York; University of Washington School of Medicine and Swedish Medical Center, Seattle, Washington; AstraZeneca, Wilmington, Delaware; University of Pennsylvania, Philadelphia, Pennsylvania; McMaster University, Hamilton, Ontario, Canada; University of California, Los Angeles, Los Angeles, California; and Scripps Clinic and Research Foundation, La Jolla, California. Department of Medicine, McMaster University Medical Centre, 1200 Main Street West Rm 3X28, Hamilton, Ontario L8N 3Z5, Canada |
| 2001 | Department of Medicine, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada |
| 2000 | 1Department of Medicine, Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada From the McMaster University Medical Centre, Hamilton, Ont. (P.B.-E., J.S.G., M.G., J.H., C.K., J.I.W.) |
| 1999 | From McMaster University, Hamilton, and University of Ottawa, Ottawa, Ontario, Canada. Department of Medicine, McMaster University, 1200 Main Street West, L8N 3G5, Hamilton, Ontario, Canada |
| 1998 | McMaster University Medical Centre, Hamilton, ON, Canada. |
Prominent publications by Jeffrey S Ginsberg
BACKGROUND: Prophylaxis is recommended following total joint replacement because of the high risk of venous thromboembolism (VTE). Postoperative low-molecular-weight heparin (LMWH) reduces the incidence of venographically detected deep vein thrombosis (DVT) to about 10-15% in total hip replacement (THR) patients. Ximelagatran is a novel, oral direct thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. We compared the efficacy and safety of ...
| Known for Ximelagatran Enoxaparin | Venous Thromboembolism | Total Hip | Vte Patients | Direct Thrombin |
BACKGROUND: Warfarin, which requires coagulation monitoring, is associated with relatively high rates of thromboembolism despite providing adequate prophylaxis. This study compared an oral direct thrombin inhibitor, ximelagatran, with warfarin in order to evaluate the safety and efficacy of the medication for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
METHODS: Following surgery, patients were randomly assigned to fixed-dose oral ximelagatran ...
| Known for Venous Thromboembolism | Total Knee Arthroplasty | Patients Ximelagatran | Pulmonary Embolism | Direct Thrombin |
Use of Antithrombotic Agents During Pregnancy The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about the use of antithrombotic agents during pregnancy is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations ...
| Known for Lmwh Pregnancy | Thrombolytic Therapy | Grade 1c | Antithrombotic Agents | Vte Women |
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
[ PUBLICATION ]
BACKGROUND: In a previous study of the prevention of venous thromboembolism after total knee replacement, the efficacy of ximelagatran, an oral direct thrombin inhibitor that does not require monitoring of coagulation or dose adjustment, was found to be similar to that of warfarin at a dose of 24 mg of ximelagatran twice daily. The purpose of the present study was to determine whether a higher dose of ximelagatran is superior to warfarin.
METHODS: This randomized, double-blind trial ...
| Known for Knee Replacement | Ximelagatran Warfarin | Venous Thromboembolism | Pulmonary Embolism Death | Administration Oral |
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis
[ PUBLICATION ]
BACKGROUND: In acute coronary syndrome without ST elevation, the role of unfractionated and low-molecular-weight heparin in aspirin-treated patients remains unclear, and there is conflicting evidence regarding the efficacy and safety of low-molecular-weight heparin (LMWH) relative to unfractionated heparin. We did a systematic overview of the randomised trials to assess the effect of unfractionated heparin and LMWH on death, myocardial infarction, and major bleeding.
METHODS: Randomised ...
| Known for Unfractionated Heparin | Acute Coronary | Major Bleeding | Death Myocardial Infarction | Untreated Control |
STUDY OBJECTIVE: To determine whether measurement of D-dimer, using an enzyme-linked immunosorbent assay (ELISA) with a cutoff of 300 ng/ml, and a latex agglutination assay with a cutoff of 500 ng/ml, is clinically useful in patients with suspected pulmonary embolism (PE).
DESIGN: Prospective cohort.
SETTING: Tertiary care referral center, university-affiliated hospital.
PATIENTS: Two hundred twenty-one consecutive patients with clinically suspected PE.
INTERVENTION: All patients had ...
| Known for Clinically Suspected | Pulmonary Embolism | Latex Agglutination | Assay Patients | Imaging Sensitivity |
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial
[ PUBLICATION ]
CONTEXT: Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple therapeutic alternative to current standard treatment of acute venous thromboembolism.
OBJECTIVE: To compare the efficacy and safety of ximelagatran with standard enoxaparin/warfarin treatment for the prevention of recurrent venous thromboembolism.
DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, noninferiority trial ...
| Known for Deep Vein Thrombosis | Enoxaparin Warfarin | Weight Heparin | Oral Ximelagatran | Venous Thromboembolism |
Background: Warfarin, which requires coagulation monitoring, is associated with relatively high rates of thromboembolism despite providing adequate prophylaxis. This study compared an oral direct thrombin inhibitor, ximelagatran, with warfarin in order to evaluate the safety and efficacy of the medication for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. Methods: Following surgery, patients were randomly assigned to fixed-dose oral ximelagatran ...
| Known for Venous Thromboembolism | Total Knee Arthroplasty | Ximelagatran Warfarin | Pulmonary Embolism | Direct Thrombin |
Jeffrey S Ginsberg: Influence Statistics
| Concept | World rank |
|---|---|
| common vascular mortality | #1 |
| pregnancy heparin | #1 |
| determinants collaborative model | #1 |
| soluble fibrin patients | #1 |
| dvt ipg | #1 |
| fibrin assay | #1 |
| management iliofemoral thrombosis | #1 |
| subcutaneous heparin pregnancy | #1 |
| pregnancy cardiovascular thrombosis | #1 |
| soluble fibrin study | #1 |
| noninvasive diagnostic tests | #1 |
| purpose pulmonary embolism | #1 |
| measured aptt | #1 |
| duration heparin | #1 |
| inr months | #1 |
| clinicians gestalt | #1 |
| serial compression | #1 |
| thromboembolism transient | #1 |
| dvt future | #1 |
| recurrent vte episode | #1 |
| dosing unfractionated heparin | #1 |
| population increases incidence | #1 |
| 11 venography | #1 |
| patients ddimer testing | #1 |
| diagnosis deep | #1 |
| clinical suspicion dvt | #1 |
| negative simplired | #1 |
| maternal morbidity disease | #1 |
| 3 unfractionated heparin | #1 |
| 5 anticoagulants pregnancy | #1 |
| prevalence thrombosis | #1 |
| immunosorbent soluble | #1 |
| develop dvt | #1 |
| pregnancy leg | #1 |
| pharmacological vte prophylaxis | #1 |
| pregnancy antithrombotic therapy | #1 |
| aptt versus | #1 |
| normal simplired ddimer | #1 |
| accurate objective tests | #1 |
| predictive reagent kits | #1 |
| patients treated dvt | #1 |
| months warfarin | #1 |
| imaging iliac | #1 |
| venous thrombosis agents | #1 |
| criteria effective agents | #1 |
| 1098 titles | #1 |
| fetus oral anticoagulants | #1 |
| suspected episode | #1 |
| moderate pretest | #1 |
| bleeding complications selection | #1 |
Open the FULL List in Excel | |
Key People For Venous Thromboembolism
Jeffrey S Ginsberg:Expert Impact
Concepts for whichJeffrey S Ginsberghas direct influence:Venous thromboembolism, Pulmonary embolism, Deep vein thrombosis, Venous thrombosis, Unfractionated heparin, Anticoagulant therapy, Deep venous thrombosis, Vein thrombosis.
Jeffrey S Ginsberg:KOL impact
Concepts related to the work of other authors for whichfor which Jeffrey S Ginsberg has influence:Venous thromboembolism, Pulmonary embolism, Deep vein thrombosis, Unfractionated heparin, Atrial fibrillation, Antiphospholipid syndrome, Oral anticoagulants.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |